20-F/A: Altamira Therapeutics Files Amendment No. 2 to 20-F, Including Audited Financials for Altamira Medica AG

Altamira Therapeutics files an amendment to its 2023 annual report to include the audited financial statements of Altamira Medica AG, as required by SEC regulations.

Summary

• Altamira Therapeutics Ltd. is filing Amendment No. 2 to its Annual Report on Form 20-F for the year ended December 31, 2023.
• The amendment includes the audited financial statements of Altamira Medica AG and related exhibits.
• The filing is required under Rule 3-09 of Regulation S-X.
• The amendment includes certifications from the Principal Executive Officer and Principal Financial Officer, as well as the consent of BDO AG regarding their report on the Medica Financial Statements.
• No other changes have been made to the original 2023 Form 20-F, and the amendment does not reflect events after the original filing date.
• The audited financial statements of Altamira Medica AG for the year ended December 31, 2023, are included.
• The filing includes a list of exhibits, including various agreements and certifications.

Sentiment

Score: 4

Explanation: The document is primarily a regulatory filing, but the inclusion of an auditor's note about 'going concern' and the reported net loss for Altamira Medica AG negatively impacts the sentiment.

Positives

• The inclusion of audited financial statements for Altamira Medica AG provides greater transparency.
• The certifications from the CEO and CFO affirm the accuracy and completeness of the report.
• The company is complying with SEC regulations by filing this amendment.

Negatives

• The auditor's report on Altamira Medica AG raises substantial doubt about the company's ability to continue as a going concern.
• Altamira Medica AG reported a net loss of CHF 1,779,505 for the year ended December 31, 2023.
• Altamira Medica AG has a shareholders deficit of CHF 93,386 as of December 31, 2023.

Risks

• Altamira Medica AG's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company's future success depends on growing product revenues, generating licensing revenues, and potentially raising further funds.
• The company is exposed to liquidity risk and may need to reduce or delay operations if it cannot secure sufficient funding.

Future Outlook

The company expects to fund its operations in the next 12 months through available cash, licensing revenues, and potential additional funding from shareholders or outside investors. The company's operations are expected to become profitable once sustainable commercial operations are achieved.

Industry Context

This filing is a routine regulatory requirement for companies listed on US stock exchanges, ensuring transparency and providing investors with up-to-date financial information. The inclusion of Altamira Medica AG's financials reflects its significance within the Altamira Therapeutics group.

Comparison to Industry Standards

• It is difficult to compare Altamira Medica AG directly to industry standards without knowing the specific segment of the pharmaceutical or OTC market in which it primarily competes.
• However, the auditor's note regarding 'going concern' is a critical point, as it indicates a higher level of financial risk than typically seen in established pharmaceutical companies.
• Comparisons could be made to other small or development-stage pharmaceutical companies, but these would need to account for differences in product pipelines, clinical trial stages, and market strategies.

Related Party Transactions

• As of December 31, 2023, Auris Medical AG held a loan granted to the Company in the amount of CHF 18,905.
• In 2023, Auris Medical AG charged the Company CHF 459,988 for R&D services and CHF 192,493 for selling, general and administrative services.
• In 2023, interest expense to related parties amounted to CHF 301,276 and interest income from related parties to CHF 1,889.
• The interest expenses and income related to Altamira Therapeutics Ltd. and its subsidiaries.

Stakeholder Impact

• Shareholders should be aware of the auditor's note regarding Altamira Medica AG's ability to continue as a going concern.
• Employees of Altamira Medica AG may face uncertainty due to the company's financial situation.
• Customers and suppliers of Altamira Medica AG should monitor the company's financial health to assess potential disruptions.

Key Dates

Keywords

Altamira Therapeutics, Altamira Medica AG, 20-F/A, Amendment, Financial Statements, Audited Financials, BDO AG, Going Concern, SEC Filing, Regulation S-X